Proteomic analysis of phosphotyrosyl proteins in the rat brain: Effect of butorphanol dependence

Journal of Neuroscience Research

Volumn 77, Issue 6, 2004, Pages 867-877

  Kim, Seong Youl ^a   Chudapongse, Nuannoi ^a   Lee, Sang Min ^b   Levin, Michael C ^b   Oh, Jae Taek ^c   Park, Hae Joon ^c   Ho, Ing K ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Mogam Biotechnology Research Institute   (South Korea)

Author keywords

Butorphanol; Dependence; MALDI MS; Phosphorylation; Proteomics

Indexed keywords

BRAIN PROTEIN; BUTORPHANOL; BUTORPHANOL TARTRATE; PHOSPHOTYROSINE; PHOSPHOTYROSYL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL METABOLISM; CHRONOPHARMACOLOGY; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSED IMMUNOELECTROPHORESIS; CYTOSKELETON; DRUG DEPENDENCE; FRONTAL CORTEX; IN VIVO STUDY; MALE; NONHUMAN; OSMOTIC MINIPUMP; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; RAT;

ANIMALS; BRAIN; BUTORPHANOL; MALE; OPIOID-RELATED DISORDERS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEINS; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 4444276053     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20214     Document Type: Article

References (32)

1. Beitner-Johnson D, Guitart X, Nestler EJ. 1993. Glial fibrillary acidic protein and the inesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J Neurochem 61:1766-1773.
2. Beranova-Giorgianni S, Giorgianni F, Desiderio DM. 2002. Analysis of the proteome in the human pituitary. Proteomics 2:534-542.
3. Brown GR. 1985. Stadol dependence: another case. JAMA 254:910.
4. Chang KJ, Wei ET, Killian A, Chang JK. 1983. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther 227:403-408.
5. Chavkin C, McLaughlin JP, Celver JP. 2001. Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol 60:20-25.
6. Dobkin AB, Arandia HY, Byles PH, Africa BF, Caruso FS, Noveck RJ. 1976. Butorphanol tartrate: 2. Safety and efficacy in balanced anesthesia. Can Anesth Soc J 23:601-608.
7. Dodge PW, Takemori AE. 1972. Effects of morphine, nalorphine and pentobarbital alone and in combination on cerebral glycolytic substrates and cofactors of rats in vivo. Biochem Pharmacol 21:287-294.
8. Edgar PF, Schonberger SJ, Dean B, Faull RLM, Kydd R, Cooper GJS. 1999. A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol. Psychiatry 4:173-178.
9. Evans WS, Bowen JN, Giordano FL, Clark B. 1985. A case of Stadol dependence. JAMA 253:2191-2192.
10. Garcia-Sevilla JA, Ventayol P, Busquets X, La Harpe R, Walzer C, Guimon J. 1997. Marked decrease of immunolabelled 68 kDa neurofilament (NF-L) proteins in brains of opiate addicts. Neuroreport 8:1561-1565.
11. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM. 1999. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 20:601-605.
12. Görg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. 2000. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037-1053.
13. Grandy DK, Hanneman E, Bunzow J, Shih M, Machida CA, Bidlack JM, Civelli O. 1990. Purification, cloning, and tissue distribution of a 23-kDa rat protein isolated by morphine affinity chromatography. Mol Endocrinol 4:1370-1376.
14. Gronborg M, Kristiansen TZ, Stensballe A, Andersen JS, Ohara O, Mann M, Jensen ON, Pandey A. 2002. A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. Mol Cell Proteomics 1:517-527.
15. Hoover RC, Williams RB. 1985. Survey of butorphanol and nalbuphine diversion in US hospitals. Am J Hosp Pharm 42:1111-1113.
16. Horan P, Ho IK. 1989. Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol Biochem Behav 34:847-854.
17. Horan P, Ho IK. 1991. The physical dependence liability of butorphanol: a comparative study with morphine. Eur J Pharmacol 203:387-391.
18. Imani-Sghiouar N, Laude-Lemaire I, Labas V, Pflieger D, Le Caër JP, Caron M, Nabias DK, Joubert-Caron R. 2002. Subproteomics analysis of phosphorylated proteins: application to the study of B-lymphoblasts from a patient with Scott syndrome. Proteomics 2:828-838.
19. Jasinski DR, Pvenick JS, Griffith JD, Gorodetzky CW, Cone EJ. 1976. Progress report from the clinical pharmacology section of the addiction research center, committee on problems of drug dependence. Proc Natl Acad Sci USA 112:120.
20. Jaw SP, Makimura M, Oh KW, Hoskin B, Ho IK. 1994. Involvement of K-opioid receptors in opioid dependence/withdrawal: studies using butorphanol. Eur J Pharmacol 257:153-160.
21. Johnston-Wilson NL, Sims CD, Hoffmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. 2000. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5:142-149.
22. Kosenko E, Llansola M, Montoliu C, Monfort P, Rodrigo R, Hernandez-Viadel M, Erceg S, Sanchez-Perez AM, Felipo V. 2003. Glutamine synthetase activity and glutamine content in brain: modulation by NMDA receptors and nitric oxide. Neurochem Int 43:493-499.
23. Kroslak T, Koch T, Kahl E, Hollt V. 2001. Human phosphatidyl- ethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling. J Biol Chem 276:39772-39778.
24. Law PY, Loh HH. 1999. Regulation of opioid receptor activities. J Pharmacol Exp Ther 28:607-624.
25. Liu JG, Anand KJ. 2001. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev 38:1-19.
26. Oh S, Kim JI, Chung MW, Ho IK. 2000. Modulation of NMDA receptor subunit mRNA in butorphanol-tolerant and -withdrawing rats. Neurochem Res 25:1603-1611.
27. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press.
28. Sherman AD, Mitchell CL. 1972. Effects of morphine and pain on brain intermediary metabolism. Neuropharmacology 11:871-877.
29. Smith SG, Davis WM. 1984. Nonmedical use of butorphanol and diphenhydramine, JAMA 252:1010.
30. Yuan X, Desiderio DM. 2003. Proteomics analysis of phosphotyrosyl- proteins in human lumbar cerebrospinal fiuid. J Proteome Res 2:476-487.
31. Zhang WB, Zhang Z, Ni YX, Wu YL, Pei G. 2003. A novel function of Goα: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells. J Neurochem 86:1213-1222.
32. Zhu H, Rockhold RW, Ho IK. 1998. The role of glutamate in physical dependence on opioids. Jpn J Pharmacol 76:1-14.